Alpha-emitter therapy Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines alpha-emitter therapy, the use of radionuclides such as actinium-225, lead-212, astatine-211 and radium-223 attached to targeting molecules to deliver high energy, short range radiation to cancer cells. It tests how fast alpha trials expand after the approval of beta emitting radioligands, and which participants capture value among developers, large pharmaceutical firms, isotope producers and treatment centres.

Clinical activity is strongest in patients who have already received a beta radioligand. In the AcTION Phase 1 study of actinium-225 PSMA-617, PSA50 response was 56.3% in patients previously treated with lutetium-177 PSMA, and 58.8% in patients treated after chemotherapy and hormonal therapy without lutetium. In the CONVERGE-01 Phase 2 study of actinium-225 rosopatamab tetraxetan, PSA50 was 40% in patients pretreated with lutetium-177 PSMA. The conclusion is that alpha therapy gives a response where beta radioligands have been used, although the cohorts are small and early.

The main safety issue is salivary gland toxicity. In the multicentre WARMTH Act retrospective study of actinium-225 PSMA therapy in 347 patients, median overall survival was 15.5 months, median progression-free survival 7.9 months, and xerostomia occurred in 236 patients, or 68%. The conclusion is that dose and fractionation strategies, rather than efficacy alone, will decide how widely alpha therapy is used.

Late-stage programmes are now under way. AstraZeneca began a Phase 3 trial of its actinium-225 PSMA therapy AZD2265 in the second quarter of 2026, Novartis projects an FDA filing for AAA817 in 2028, Convergent Therapeutics is moving CONV01-α toward Phase 3, and Sanofi and Orano Med reported that lead-212 AlphaMedix met its primary endpoints in a Phase 2 study in 2025. The conclusion is that the first approvals of actinium-225 therapies are likely in the latter half of this decade, with supply and toxicity as the limits.

The brief treats alpha-emitter therapy as a high-impact category with a ten year horizon to 2036. It identifies which cancers, regions and operators scale first and what each means for developers, large pharmaceutical firms, isotope producers and treatment centres.

It is a focused 104-page decision brief for radiopharma firms, oncology centres and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which cancers scale first and who captures value.

Alpha particles deposit high energy over a distance of a few cell diameters. This damages cancer cells while limiting harm to surrounding tissue, and it works on cells that resist beta radiation.

Radium-223 is the approved alpha emitter for bone metastases. Actinium-225 is attached to PSMA, somatostatin and antibody targeting molecules, and lead-212 serves as a generator based alpha source.

Targets in development include PSMA in prostate cancer, SSTR2 in neuroendocrine tumours, MC1R in melanoma, FAP and GPC3.

Uses are advanced prostate cancer, neuroendocrine tumours, melanoma and other solid cancers, each under radiopharmaceutical regulation.

The limits are salivary gland and kidney toxicity, limited supply of actinium-225 and lead-212, and competition from beta radioligands. The decade turns on whether registrational trials confirm survival benefit with acceptable toxicity.

The alpha-emitter therapy market, covering marketed alpha-emitter therapy sales, related licensing and collaboration revenue, and related isotope supply and manufacturing services for alpha radioligand programmes, is valued at USD 0.4–0.6 billion in 2026 and is projected to reach USD 8.04–12.06 billion by 2036, at a CAGR of 35%.

The 2026 base rests on sales of the approved radium-223 therapy, licensing and collaboration income, and isotope supply and manufacturing services. Growth then follows the first approvals of actinium-225 therapies, lead-212 programmes and wider tumour types.

The forecast is sensitive to registrational results, toxicity management, actinium-225 and lead-212 supply and competition from beta radioligands. Regionally, North America leads on trials and approvals, Europe on isotope production and research, and Asia-Pacific and Africa on investigator led studies.

The base case assumes Phase 3 trials report around 2028 and 2029 and the first approvals follow, giving the inflection in 2032. An accelerated case assumes strong survival data and earlier filings, bringing the inflection to 2030 and lifting the 2036 value to the top of the range. A delayed case assumes toxicity limits dose, supply stays short or trials miss their endpoints, holding growth at the bottom of the range.

Growth drivers

• Patients who progress after beta radioligand therapy.
• Response in patients pretreated with lutetium-177.
• Late-stage trials in prostate and neuroendocrine tumours.
• Large pharmaceutical investment in radiopharma.

Enablers

• Venture funding and financing rounds.
• Biopharma licensing and partnerships.
• Public research funding.
• Alpha isotope supply capacity.

Restraints and barriers

• Salivary gland toxicity and dose limits.
• Limited actinium-225 and lead-212 supply.
• Competition from beta radioligands and other modalities.
• Cost and treatment centre licensing.

The direction of alpha-emitter therapy is set by the need for options after beta radioligand therapy, regulation, new targets and alpha isotopes, treatment centre adoption and licensing, and manufacturing cost.

The key participants in alpha-emitter therapy include Bayer AG, Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Sanofi, Eli Lilly and Company, Merck & Co., Inc., Perspective Therapeutics, Inc., Convergent Therapeutics, Inc., AdvanCell Isotopes Pty Ltd, Orano SA, Actinium Pharmaceuticals, Inc., Oncoinvent ASA, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., Cardinal Health, Inc., TerraPower, LLC, NorthStar Medical Radioisotopes, LLC, Niowave, Inc., Curium, SHINE Technologies, LLC, ARTBIO, Inc., Alpha Tau Medical Ltd., Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Society of Nuclear Medicine and Molecular Imaging, European Association of Nuclear Medicine, American Society of Clinical Oncology, European Society for Medical Oncology, U.S. Department of Energy, International Atomic Energy Agency, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, U.S. Nuclear Regulatory Commission, International Organization for Standardization, International Council for Harmonisation and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as alpha-emitter therapy matures.

Bayer holds the approved radium-223 therapy, AstraZeneca, Novartis, Bristol-Myers Squibb and Sanofi hold late-stage actinium-225 and lead-212 programmes, and Perspective Therapeutics, Convergent Therapeutics and AdvanCell lead independent development, while isotope producers, hospitals, regulators and standards bodies shape how fast these therapies reach patients. Competitive intensity is moderate in 2026 because few products are late stage, and it rises as Phase 3 data arrive.

Where value migrates.

In 2026 value sits with the holder of the approved radium-223 therapy and with the large firms that own late-stage actinium-225 programmes. By 2032 it moves toward companies with approved alpha radioligands, because registrational data and supply contracts decide who reaches the market first. By 2036 it settles in integrated isotope, drug and delivery networks that secure alpha isotopes and place production near treatment sites. Margins hold for products with survival benefit and narrow for late followers on crowded targets such as PSMA.

The signals converge on late-stage progress and constrained supply. Phase 3 trials of actinium-225 therapies began in 2026, response rates of 40% to 59% were seen in lutetium-177 pretreated and other prostate cancer cohorts, and large firms are adding lead-212 programmes through partnerships. Each signal supports growth, and the studies are small and early.

Structural limits show where progress could slow: salivary gland toxicity, limited isotope supply and competition from beta radioligands. The brief therefore tracks four indicators: Phase 3 readouts, first filings, toxicity rates at registrational doses and alpha isotope capacity.

Prostate cancer after beta radioligand therapy, then neuroendocrine tumours and first line prostate cancer, then other solid tumours are the expected order of development.